GleamWall
中文EN

PTGX Protagonist Therapeutics, Inc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1377121 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY163.7%
TTM net income YoY645.5%
TTM EPS YoY616.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin58.6%
Net margin62.0%
FCF margin19.8%
EBITDA margin58.9%

Returns

ROE39.6%
ROA37.0%
ROIC (approx.)56.5%
Asset turnover0.60x

Leverage & solvency

Liabilities / assets5.4%
Debt / equity0.00x
Current ratio19.85x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.32x
Accruals ratio25.1%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$274.41M$213.47M$56.37M$7.44M$4.71M$5.55M$28.32M$170.64M
Cost of revenue$1.10M———————
Gross profit$273.31M———————
R&D expense$41.27M$42.06M$46.74M$46.36M$40.00M$37.04M$35.89M$34.90M
SG&A expense$13.70M$12.65M$13.28M$11.43M$11.13M$10.55M$11.74M$8.95M
Operating income$218.33M$158.77M-$3.65M-$50.35M-$46.42M-$42.04M-$19.31M$126.78M
Pretax income$226.57M$165.11M$2.28M-$43.72M-$39.34M-$34.60M-$11.65M$133.66M
Income tax$6.56M$2.27M-$1.50M$666,000$0$172,000$0$1.99M
Net income$220.01M$162.85M$3.78M-$44.38M-$39.34M-$34.77M-$11.65M$131.67M
EBITDA$218.74M$159.16M-$3.24M-$49.98M-$46.06M-$41.74M-$19.07M$126.90M
EPS (basic)3.322.470.06—-0.62-0.55-0.19—
EPS (diluted)3.072.290.05—-0.62-0.55-0.19—
Weighted avg. shares (diluted)71.73M71.01M70.49M—63.77M63.51M62.96M—
Balance sheet
Cash & equivalents$498.30M$420.08M$193.71M$128.39M$113.71M$168.54M$139.65M$97.47M
Short-term investments$301.77M$362.50M$354.07M$438.97M$462.40M$401.92M$434.71M$321.66M
Current assets$1.10B$807.15M$613.46M$577.57M$586.42M$602.53M$605.86M$591.64M
PP&E, net$3.32M$3.46M$3.78M$3.86M$4.10M$4.11M$3.53M$3.19M
Total assets$1.15B$885.54M$697.46M$668.19M$701.69M$718.01M$742.13M$744.73M
Current liabilities$55.46M$37.18M$34.55M$45.44M$44.94M$35.51M$35.11M$47.40M
Total liabilities$61.64M$44.00M$41.99M$53.48M$56.25M$49.99M$53.08M$69.43M
Shareholders' equity$1.08B$841.54M$655.47M$614.71M$645.44M$668.02M$689.05M$675.29M
Shares outstanding65.22M64.67M64.23M62.58M62.45M62.11M61.93M61.04M
Cash flow statement
Operating cash flow-$23.22M$219.05M-$48.94M-$36.98M-$1.94M-$28.78M$125.36M-$29.18M
Capital expenditure$237,000$168,000$215,000$144,000$88,000$813,000$545,000$310,000
Free cash flow-$23.46M$218.88M-$49.16M-$37.12M-$2.02M-$29.59M$124.82M-$29.49M
Investing cash flow$93.43M-$2.43M$90.89M$48.81M-$58.55M$54.81M-$94.40M-$8.72M
Financing cash flow$8.01M$9.74M$23.37M$2.84M$5.66M$2.92M$11.44M$4.03M
Depreciation & amortization$409,000$397,000$407,000$376,000$361,000$304,000$239,000$118,000
Stock-based compensation$14.36M$14.04M$14.52M$10.70M$10.56M$10.91M$13.80M$9.09M

Free plan shows the latest 8 periods; Pro shows all 47 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.